VEGF Antikörper (C-Term)

Produktnummer ABIN6242881

Produktdetails anti-VEGF Antikörper

Target: VEGF (Vascular Endothelial Growth Factor (VEGF))

Bindungsspezifität: C-Term

Reaktivität: Human

Wirt: Kaninchen

Klonalität: Polyklonal

Konjugat: Dieser VEGF Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Aufreinigung: This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS.

Immunogen: This VEGF antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide selected from the C-terminal region of human VEGF Antibody.

Klon: RB11705

Isotyp: Ig Fraction

Anwendungsinformationen

Applikationshinweise: WB: 1:2000. WB: 1:2000. IHC-P: 1:10~50

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Buffer: Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C,-20 °C

Haltbarkeit: 6 months

Details zu VEGF

Target: VEGF (Vascular Endothelial Growth Factor (VEGF))

Andere Bezeichnung: VEGF (VEGF Produkte)

Synonyme: MVCD1 antikoerper, VEGF antikoerper, VPF antikoerper, Vegf antikoerper, Vegf120 antikoerper, Vegf164 antikoerper, Vegf188 antikoerper, Vpf antikoerper, VEGF-A antikoerper, VEGF164 antikoerper, eVEGF120 antikoerper, eVEGF164 antikoerper, vegf-a antikoerper, vegf antikoerper, vascular endothelial growth factor A antikoerper, vascular endothelial growth factor A L homeolog antikoerper, vascular endothelial growth factor antikoerper, vascular endothelial growth factor precursor antikoerper, VEGFA antikoerper, Vegfa antikoerper, vegfa.L antikoerper, VEGF antikoerper, vegf antikoerper

Hintergrund: Embryonic vascular system undergoes a series of complex, highly regulated series of events involving differentiation, migration and association of primitive endothelial cells. This process is termed vasculogenesis. A further remodeling of the primitive vascular system forms the mature cardiovascular system. This process is known as angiogenesis (sprouting of new capillary vessels from pre-existing vasculature). Angiogenesis accounts for the formation of vasculature into previously avascular organs such as brain and kidney. Angiogenic activity in the adult is required during the normal tissue repair, and for the remodeling of the female reproductive organs (ovulation and placental development). Certain pathological conditions, such as tumor growth and diabetic retinopathy, also require angiogenesis. Study of tumor angiogenesis has led to the identification of several proteins including basic fibroblast growth factor (bFGF) and vascular endothelial growth factor. VEGF acts by interacting with a family of largely endothelial-specific receptor tyrosine kinases that includes VEGFR-1 (flt-1), VEGFR-2 (flk-1/KDR), and VEGFR-3/Flt-4. Disruption of VEGFRs interferes with differentiation of endothelial cells and it is lethal for the embryo. VEGF is a heparin-binding glycoprotein that is secreted as a homodimer of 45 kDa.

Molekulargewicht: 27042

NCBI Accession: NP_001020537, NP_001020538, NP_001020539, NP_001020540, NP_001020541, NP_001028928, NP_001165093, NP_001165094, NP_001165095, NP_001165096, NP_001165097, NP_001165098, NP_001165099, NP_00

UniProt: P15692